FTC v. Actavis - Where do Hatch-Waxman settlements go from here?

FTC v. Actavis - Where do Hatch-Waxman settlements go from here?

Speaking Engagement
On June 17, 2013, the Supreme Court decided Federal Trade Commission v. Actavis, Inc., which resolved a circuit split over the appropriate antitrust standard to apply when evaluating "reverse payment" Hatch-Waxman patent litigation settlements. This decision has significant consequences for settlements in branded vs. generic abbreviated new drug application (ANDA) litigation in the pharmaceutical industry.

WilmerHale Partner Mark Ford is a featured speaker at this Boston Bar Association event, and will be presenting an antitrust analysis of reverse payment settlements in Hatch-Waxman cases.

Read More About the Event

Speakers

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.